Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Mentally competent adults, who have signed an informed consent form after having received a detailed explanation of the study protocol.~2. Male or female subjects 18-50 years who are either healthy or have a stable medical condition.~3. Able to understand and comply with all study procedures and to complete study diaries~4. Individuals who can be contacted throughout the study and are available for all study visits~5. Females should either be using secure contraceptive precautions including:~   * the oral contraceptive pill~  * condom/barrier contraception~  * partner has had a vasectomy~  * be surgically sterilised, or~  * post-menopausal (defined as at least two years since the last menstrual period)~Exclusion Criteria:~1. Any clinically significant concurrent illness or unstable medical condition including: malignant tumours, autoimmune illnesses (including rheumatoid arthritis), acute or progressive renal or hepatic pathology, chronic obstructive pulmonary disease requiring oxygen therapy, and any active neurological disorder.~2. Individuals with a history of anaphylaxis or serious reactions to vaccines; hypersensitivity to influenzal viral protein, neomycin or polymixin, or products containing mercury.~3. Persons with known immunosuppressive disease or who use systemic immunosuppressive drugs or other drugs listed in section 8 of the British National Formulary (BNF) or chloroquine, gold or penicillamine or other drugs listed in section 10.1.3 of the BNF to suppress a chronic disease process, or have received in the last 6 months radiotherapy or chemotherapy.~4. Subjects who are at high risk of developing illnesses of the immune system.~5. Individuals who are taking immunostimulant therapy or interferon~6. Individuals who have received blood products or immunoglobulins parenterally during the preceding three months.~7. Women should not be pregnant or lactating.~8. Women who refuse to use a reliable contraceptive method throughout the study~9. Known or suspected drug abuse.~10. Individuals who have received another vaccine or investigational medicinal product in the preceding 2 weeks.~11. Unable to lead an independent life either physically or mentally~12. Regularly drink more than 40 units of alcohol weekly~13. Individuals who have had acute respiratory pathology or infections requiring systemic antibiotic or antiviral therapy during the preceding 7 days (chronic antibiotic therapy for prevention of urinary tract infections is acceptable).~14. Individuals who had a temperature \>38oC in the preceding 3 days.~15. Individuals who, in the opinion of the investigator, have conditions that might complicate interpretation of the study results.~16. Individuals who have had confirmed pandemic influenza H1 infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: ACTIVE_COMPARATOR): adjuvanted influenza vaccine
- Vaccine 2 (Type: ACTIVE_COMPARATOR): non-adjuvanted vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete